Case Report

A case report of vulvar carcinoma in situ treated with sinecatechins with complete response

Natasha Gupta c,⁎, Ernesto Rodriguez a, Vaagn Andikyan a, Stacy P. Salob b, Dennis Chi a

a Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
b Department of Dermatology, Weill Cornell Medical Center, 1300 York Avenue, New York, NY 10021, USA
c Department of Obstetrics and Gynecology, Mount Sinai Hospital, Chicago, Illinois 60608, USA

A R T I C L E   I N F O

Article history:
Received 21 May 2013
Accepted 24 June 2013
Available online 1 July 2013

Keywords:
Vulvar intraepithelial neoplasia
Carcinoma in situ
Immunocompromised
Sinecatechins

Introduction

Vulvar intraepithelial neoplasia (VIN) is a dysplastic premalignant condition that affects the vulvar squamous epithelium. It is classified into usual and differentiated types. If left untreated, VIN may progress to invasive cancer within 1–7 years (Jones et al., 2005). Although rare, VIN has become an increasingly common problem in younger women <50 years of age with a reported 392% increase in incidence from 1994–1997 (Joura et al., 2000). Interestingly, it is not rare to diagnose invasive cancer at the time of surgery for VIN, with a reported incidence of up to 5% (ACOG, 2011). A similar trend has been observed in vulvar cancer patients with a striking increase in incidence noted in the 40–49 years age group (Joura et al., 2000). High risk human papillomavirus (HPV) infection, human immunodeficiency virus infection, smoking, and other pelvic neoplasia are some of the documented risk factors for development of VIN (ACOG, 2011). Recognized treatment modalities include partial superficial skinning vulvectomy, wide local excision, CO2 laser ablation, topical ointments (Imiquimod 5%), and 5-aminolevulinic acid-based photodynamic therapy (Hillemanns et al., 2006).

In 2006, Sinecatechins 15% ointment (Veregen®, PharmaDerm®), was the first botanical drug approved by the Food and Drug Administration for the treatment of external anogenital warts (U.S. Food and Drug Administration and Center for Drug Evaluation and Research, 2006). It is a formulation of a variety of catechins, a type of polyphenol with potent antioxidant activity. It has been identified for its immunostimulatory, antitumor, and antiproliferative properties (Stockfleth et al., 2008). Although Veregen® has an established role in complete clearance of anogenital warts; it has not been used for the treatment of VIN. We report a case of a woman with multifocal Usual-type VIN, warty type disease who was treated with Sinecatechins 15% ointment.

Case Report

A 45-year-old female with myelodysplastic syndrome, 10 months after stem cell transplant (CD4 count 143 cell/μL), presented her primary care physician complaining of pruritic lesions on her vulva. She had no other pertinent risk factors. Physical exam revealed erythematous papules, plaques and ulcerated lesions on the vulva. An office biopsy was obtained which showed high grade VIN and squamous cell carcinoma in situ (CIS). The patient was then referred to the gynecologic oncology service at our institution for further workup and management. She was noted to have extensive multifocal and multicentric disease (Fig. 1). After performing further biopsies in the operating room, all biopsy specimens were then reviewed by our gynecologic pathologists and diagnosed as Usual-type VIN, warty subtype, with HPV changes and CIS. Initially, our recommendations included wide local excision of the lesions. However, due to its multifocal involvement and need for excision of the clitoris with extensive reconstruction, more conservative alternatives were considered. We prescribed topical Imiquimod 5% ointment, twice weekly. Patient was followed every two weeks in clinic and after 8 weeks of treatment, she failed to show any clinical response. In addition, due to extreme pain with application, patient was unable to tolerate the full course, despite use of narcotics and pudendal block.

Consequently, we prescribed Veregen® ointment, to be used three times a day for six weeks. Four weeks after start of therapy, visible improvement in the vulvar lesions was noted. The patient reported some pain and discomfort at the application sites, but stayed motivated to complete the treatment, as her lesions appeared to be resolving. At the end of 6 weeks, examination revealed complete resolution of all lesions, with mild scarring on the vulva (Fig. 2). Confirmatory
 iniciating medical treatment. It is also recommended to prevent invasive disease must be excluded with colposcopy and biopsies prior to vulvar anatomy and function, particularly in younger women. Invasive therapy, provided there is no coexistent invasive cancer. Conversely, higher grade lesions may require aggressive surgical treatment due to noticeable improvement with use. The exact mechanism of action of Sinecatechins in wart regression is yet to be identified, but it has been shown to inhibit a broad range of enzymes and kinases involved in the generation of inflammatory mediators. Its wide array of biological activities shows great therapeutic potential in treatment of other HPV related tumors (Tyring, 2012).

To our knowledge, this is the first report of successful treatment of VIN/CIS with Sinecatechins 15%. Prospective studies are warranted to investigate its role in the treatment of VIN or other pelvic dysplastic diseases.

**Conflict of interest statement**

The authors have no conflict of interest to report.

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal upon request.

**References**

ACOG Committee Opinion No. 509, 2011. Management of vulvar intraepithelial neoplasia. Obstet. Gynecol. 118 (5), 1192–1194.

Gross, G., et al., 2007. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J. Eur. Acad. Dermatol. Venereol. 21 (10), 1404–1412.

Hillemanns, P., et al., 2006. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN); CO2 laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol. Oncol. 100 (2), 271–275.

Jones, R.W., Rowan, D.M., Stewart, A.W., 2005. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet. Gynecol. 106 (6), 1319–1326.

Joura, E.A., et al., 2000. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J. Reprod. Med. 45 (8), 613–615.
Stockfleth, E., et al., 2008. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br. J. Dermatol. 158 (6), 1329–1338.

Tatti, S., et al., 2008. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet. Gynecol. 111 (6), 1371–1379.

Tyring, S.K., 2012. Effect of Sinecatechins on HPV-Activated Cell Growth and Induction of Apoptosis. J. Clin. Aesthet. Dermatol. 5 (2):p. 34-41.

U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2006. Approval letter Veregen™ Ointment, 15%, NDA 021902. U.S. Food and Drug Administration, Washington (DC).